N/A
Completed N=65
Thoracic Paravertebral Block Using Ropivacaine and Dexmedetomidine
Pain, Postoperative
Source: ClinicalTrials.gov NCT02814890 ↗
Enrolled (actual)
65
Serious AEs
5.0%
Results posted
Aug 2020
Primary outcomePrimary: Postoperative Pain (Pain Scores) Intensity Measure — 1; 3 units on a scale — p=0.001
Summary
The hypothesis of the study is whether dexmedetomidine plus local anesthetic ropivacaine could extend the pain relieve time compared with only ropivacaine when thoracic paravertebral block is performed at the end of video-assisted pneumonectomy.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Postoperative Pain (Pain Scores) Intensity Measure |
1; 3 | 0.001 sig |
| SECONDARY Patient Satisfaction |
0; 0; 0; 0; 1; 7 | — |
| SECONDARY Number of Participants With Postoperative Rescue Analgesic Administration |
1; 1 | — |
| SECONDARY Adverse Events |
5; 3 | >0.05 |
Eligibility Criteria
Inclusion Criteria
- ASA physical status I-II grade
- Undergoing elective video-assisted pneumonectomy under general anesthesia.
- Participants aged from 30-70 years old.
Exclusion Criteria
- Refusal for paravertebral block
- Inability to obtain informed consent
- Coagulation disorders, neuropathy, or body mass index greater than 40 kg/m2
- Pregnancy
- Infections at the site of injection for the paravertebral block
- Allergy to local anesthetics or alpha-2 adrenergic agonists
- Heart block or bradycardia (heart rate < 60 beat per minute)
- Clinically significant cardiovascular, pulmonary, renal, or hepatic diseases
Data sourced from ClinicalTrials.gov (NCT02814890). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.